Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Separizumab plus chemotherapy as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2300078954Phase 4Not yet recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Sapelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Changzhou First People's Hospital. Primary endpoint: Pathologic complete response. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
Sapelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2300078954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078954.